Why the study?
Evidence from event-based randomized trials is lacking to guide treatment decisions for many patients with stage 1 hypertension, leaving a guidance gap for those with low 10-year cardiovascular risk.
What are the therapy options for adults with stage 1 hypertension and low 10-year ASCVD risk who fail to meet BP goals after 6 months of lifestyle therapy?
What are the therapy options for adults with stage 1 hypertension and low 10-year ASCVD risk who fail to meet BP goals after 6 months of lifestyle therapy?
No takes yet. Share an insight, caveat, or question.
Offers therapy options after lifestyle failure in low-risk stage 1 hypertension; extends 2017 guidelines into this evidence gap.
Jones et al. (2021) conducted a review in Stage 1 hypertension with low 10-year ASCVD risk. Therapy options for stage 1 hypertension was evaluated. This scientific statement provides complementary guidance and therapy options for managing adults with untreated stage 1 hypertension and low ASCVD risk who fail 6 months of lifestyle therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: